Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor.
Breast and prostate cancers are hormone-sensitive malignancies that afflict millions of women and men. Although prolactin (PRL) is known as a survival factor that supports tumor growth and confers chemoresistance in both cancers, its precise role in these tumors has not been studied extensively. Growth hormone and placental lactogen also bind PRL receptor (PRLR) and mimic some of the actions of PRL. Blockade of the PRLR represents a novel treatment for patients with advanced breast or prostate cancer with limited therapeutic options. This review discusses different approaches for generating PRLR antagonists. Emphasis is placed on technological advances which enable high-throughput screening for small molecule inhibitors of PRLR signaling that could serve as oral medications.
Jacobson
Eric M
EM
Division of Endocrinology, Diabetes and Metabolism, University of Cincinnati, Cincinnati, OH 45267-0567, USA.
Hugo
Eric R
ER
Tuttle
Traci R
TR
Papoian
Ruben
R
Ben-Jonathan
Nira
N
D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D002277:Carcinoma / Q000628:therapy*; D005260:Female; D057166:High-Throughput Screening Assays / Q000379:methods; D006727:Hormone Antagonists / Q000302:isolation & purification / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008954:Models, Biological; D008958:Models, Molecular; D058990:Molecular Targeted Therapy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D011981:Receptors, Prolactin / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D035703:Therapies, Investigational / Q000379:methods
D006727:Hormone Antagonists; D011981:Receptors, Prolactin